Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology

被引:86
作者
Eikenboom, JCJ [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Haematol, Haemostasis & Thrombosis Res Ctr, NL-2300 RC Leiden, Netherlands
关键词
von Willebrand disease; von Willebrand factor; drug therapy; antibodies; factor VIII; congenital; genetics; mutation;
D O I
10.1053/beha.2001.0139
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
von Willebrand disease type 3 is the most severe form of this condition. Patients present with a moderate-to-severe bleeding tendency. The plasma von Willebrand factor level in these patients is very low or undetectable. Although rare, von Willebrand disease type 3 is of major interest because of its severe clinical presentation, the need for replacement therapy and the risk of occurrence of alloantibodies after the infusion of plasma concentrates. The inheritance of type 3 disease is typically autosomal recessive. The parents are often consanguineous, although compound heterozygous inheritance does occur. The molecular basis of von Willebrand disease type 3 has recently been studied in detail, several molecular defects being identified. This chapter will focus on the clinical and molecular aspects of type 3 von Willebrand disease.
引用
收藏
页码:365 / 379
页数:15
相关论文
共 86 条
[71]  
Schneppenheim R, 1999, THROMB HAEMOSTASIS, P283
[72]  
Schwarz HP, 1997, THROMB HAEMOSTASIS, V78, P571
[73]   GENE DELETIONS CORRELATE WITH THE DEVELOPMENT OF ALLOANTIBODIES IN VONWILLEBRAND DISEASE [J].
SHELTONINLOES, BB ;
CHEHAB, FF ;
MANNUCCI, PM ;
FEDERICI, AB ;
SADLER, JE .
JOURNAL OF CLINICAL INVESTIGATION, 1987, 79 (05) :1459-1465
[74]   USEFULNESS OF PATIENT INTERVIEW IN BLEEDING DISORDERS [J].
SRAMEK, A ;
EIKENBOOM, JCJ ;
BRIET, E ;
VANDENBROUCHE, JP ;
ROSENDAAL, FR .
ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (13) :1409-1415
[75]   FAMILY STUDIES IN VONWILLEBRANDS DISEASE BY ANALYSIS OF RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISMS AND AN INTRAGENIC VARIABLE NUMBER TANDEM REPEAT (VNTR) SEQUENCE [J].
STANDEN, GR ;
BIGNELL, P ;
BOWEN, DJ ;
PEAKE, IR ;
BLOOM, AL .
BRITISH JOURNAL OF HAEMATOLOGY, 1990, 76 (02) :242-249
[76]   Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease [J].
Tout, H ;
Obert, B ;
Houllier, A ;
Fressinaud, E ;
Rothschild, C ;
Meyer, D ;
Girma, JP .
THROMBOSIS AND HAEMOSTASIS, 2000, 83 (02) :274-281
[77]   DETECTION OF HETEROZYGOTES FOR RECESSIVE VONWILLEBRANDS DISEASE BY ASSAY OF ANTIHEMOPHILIC-FACTOR-LIKE ANTIGEN [J].
VELTKAMP, JJ ;
VANTILBU.NH .
NEW ENGLAND JOURNAL OF MEDICINE, 1973, 289 (17) :882-885
[78]   ASSEMBLY AND ROUTING OF VONWILLEBRAND-FACTOR VARIANTS - THE REQUIREMENTS FOR DISULFIDE-LINKED DIMERIZATION RESIDE WITHIN THE CARBOXY-TERMINAL-151 AMINO-ACIDS [J].
VOORBERG, J ;
FONTIJN, R ;
CALAFAT, J ;
JANSSEN, H ;
VANMOURIK, JA ;
PANNEKOEK, H .
JOURNAL OF CELL BIOLOGY, 1991, 113 (01) :195-205
[79]   STABILIZATION OF FACTOR-VIII IN PLASMA BY VON WILLEBRAND FACTOR - STUDIES ON POSTTRANSFUSION AND DISSOCIATED FACTOR-VIII AND IN PATIENTS WITH VON WILLEBRANDS DISEASE [J].
WEISS, HJ ;
SUSSMAN, II ;
HOYER, LW .
JOURNAL OF CLINICAL INVESTIGATION, 1977, 60 (02) :390-404
[80]  
WEISS HJ, 1982, NEW ENGL J MED, V307, P127